Introduction
The Wiskott-Aldrich syndrome (WAS) is an X-linked condition clinically characterized by profound and progressive immunodeficiency, eczema and thrombocytopaenia. 1, 2 It is caused by heterogeneous mutations within the WAS gene, [3] [4] [5] [6] leading to absence of protein function in most of the cases. 2, 7 WASp expression is restricted to haematopoietic cells, [8] [9] [10] so its absence affects all lineages of the haematopoietic system. WASp deficiency affects mainly T cells, dendritic cells, macrophages and platelets. WAS T cells are unable to respond to T-cell receptor-mediated activation and proliferation, [11] [12] [13] [14] macrophages and dendritic cells cannot form podosomes in response to activating stimuli, 3, 15 platelets also have impaired function. 7, 16 This broad range of manifestations is explained by WASp function, which is tightly associated with the actin cytoskeleton formation, especially in actin polymerization. 3, 11, 17, 18 A successful therapy for WAS can be achieved by allogenic bone marrow (BM) stem cell transplantation 19, 20 or unrelated umbilical cord blood transplantation when a compatible donor is not available, 21 but the risk of graft vs host disease and rejection cannot be excluded in any case. [19] [20] [21] To overcome these limitations, gene therapy using autologous haematopoietic stem cells (HSCs) is a real alternative for treating WAS patients.
Gene therapy vectors for WAS must be well regulated, as transgene expression will be needed in the whole haematopoietic lineage at a certain concentration depending on the cell type. Recently, we have shown that overexpression of WASp in non-haematopoietic cells reduces cell viability by disturbing the cytoskeleton. 22 Moreover, overexpression of WASp homologues may contribute to cancer cell invasion and metastasis. 23 This points out the importance of gene therapy vectors with the capacity to express the transgene in the right cells, at the right levels. We and others demonstrated that an human immunodeficiency virus-based, SIN lentiviral vector (LV) carrying a 500-bp fragment of the endogenous WAS proximal promoter, upstream of the WAS cDNA (WW), achieved transgene levels equivalent to normal cells that completely restored the abnormal phenotype of T-cell lines derived from WAS patients. 24, 25 However, WAS gene therapy vectors should be able to give a physiologic-like profile of expression in all the haematopoietic lineages as T cells are not the only affected cell type. The expression levels of WASp are well documented in a wide variety of mature blood cells. 8, 10 However, little is known about WAS promoter regulation and WASp expression profile during haematopoiesis. We and others have demonstrated that transduction of either human 24, 26 or murine 27, 28 progenitor cells is possible using LV that harbour WAS different promoters and that the differentiation potential is not perturbed by the presence of the inserted vector. 26 However, up to date, no report exists describing in detail the expression profile of LVs bearing different WAS promoter fragments during the differentiation from human stem cells/early progenitors to all human haematopoietic lineages in vitro and in vivo. Thus, we focused on the performance of WE vector, derived from WW, in which WAS cDNA was replaced by enhanced green fluorescent protein (eGFP) and expressed from the 500-bp fragment of the WAS proximal promoter. We studied the transgene regulation during in vitro myeloid differentiation by comparing vector-driven eGFP with the endogenous WASp expression profile before and after haematopoietic differentiation, revealing very low expression levels in macrophages and erythroid cells. We therefore designed a new vector (AWE), by inserting into WE vector a 386-bp fragment of the alternative WAS promoter, which is proposed to be important during myeloid differentiation. 29, 30 Here we present for the first time an extensive comparison, in vitro and in vivo, of the expression profiles of LV bearing proximal and alternative WAS promoter fragments throughout human haematopoiesis.
Results
Reduced expression from the 500-bp fragment of the WAS proximal promoter in hCD34 + -derived macrophages and erythroid cells A successful gene therapy for WAS could be achieved by ex vivo modification and re-infusion of patient's corrected HSCs. It was previously demonstrated that WAS mRNA and protein are expressed at similar levels among adult blood-circulating cells. 10 Therefore, we wanted to evaluate if our previously characterized WAS gene therapy lentivector could maintain a physiologic profile of expression throughout haematopoiesis. Due to the very low availability of HSCs from WAS patients, we applied healthy donor HSCs to study vector behaviour. The LVs WE, in which the WAS gene was replaced by eGFP under the control of a 500-bp fragment of the WAS proximal promoter, and SE (eGFP under spleen focus-forming virus (SFFV) ubiquitous promoter) have been described before 24, 31 and are shown in Figure 1a . Highly purified CD34 + cells were transduced with WE and SE vectors at multiplicity of infection (MOI) of 10 and part was kept in serum-free medium under proliferating conditions while the rest of the cells were differentiated into myeloid lineages using a semisolid medium that allows the development of myeloid cells (see Materials and methods). To allow a true comparison between vector expression levels, we routinely confirmed by quantitative PCR that a transduction efficiency of 20-40% correlated with 1-2 copies of vector per transduced cell (WE mean values for integrated copies per transduced cell were 1.5 in proliferating CD34 + cells, 1.3 in granulocytic colonies (CFU-G), 1.5 in monocytic/macrophagic colonies (CFU-M) and 1.9 in erythroid colonies (CFU-E); for SE vector, values were 1.0 in proliferating CD34 + cells, 0.8 in CFU-G, 1.0 in CFU-M and 1.4 in CFU-E; see Materials and methods). Both vectors achieved efficient and stable eGFP expression as well as mean fluorescence intensity (MFI) over time in culture under proliferating conditions (data not shown). However, at day 15 of myeloid differentiation, it was clear that the WE vector behaved differently depending on the colony type when analysed by fluorescence microscopy. Green fluorescence intensity from WE-transduced CFU-G colonies was much higher than that from WE-transduced erythroid (BFU-E) and CFU-M colonies, indicating reduced levels of eGFP expression in erythroid and macrophagic cells (data not shown).
To quantify transgene expression variation, an average of 100 colonies of each cell type was pooled and analysed by flow cytometry (FACS). In Figure 1b, Figure 1b ). However, the WE vector exhibited a sevenfold drop in WE transgene expression for BFU-E and a 3.5-fold drop for CFU-M as compared to CD34 + cells (MFI-Inc BFU-E ¼ 3.3 and MFI-Inc CFU-M ¼ 6.5 vs MFI-Inc CD34 + cells ¼ 21.7). In contrast, SE vectors showed no significant variation in expression levels in all colony types and they were similar to the ones obtained in CD34 + cells. As vector copy number was 1-2 per transduced cell for WEand SE-transduced cells, we can relate the observed differences in eGFP expression levels to a distinct promoter activity. This may suggest a reduced WAS promoter activity of WE vector in monocytic and erythroid cells.
eGFP expression from WE vector mimics WASp endogenous expression profile in granulocytes but not in macrophages or erythroid cells It will be important for gene therapy of WAS patients to correct the WASp deficiency in the different haematopoietic lineages to normal endogenous levels. Thus, to determine if the difference in expression within the WEtransduced population correlated with a physiologic behaviour of the promoter, we compared eGFP expression with endogenous WASp expression levels in the different myeloid colony types. We studied endogenous WASp expression by quantitative western blot, using the protein extracellular signal-regulated protein kinase as a loading control. A representative experiment is shown in Figure 1c , where it can be observed that there is barely any variation in the levels of endogenous WASp expression between proliferating CD34 + cells and mye- (Figure 1d , N ¼ 8; P ¼ not significant, dashed bars).
In parallel, we compared these ratios with the ratios in MFI-Inc of each WE-and SE-transduced colony type relative to the MFI-Inc of the CD34 + population. In Figure 1d (white bars), it can be observed that the ratio between the MFI-Inc of WE-transduced CFU-G colonies and the proliferating CD34 + cells (WE-CFU-G/CD34) is close to one, resembling endogenous WASp expression profile. This suggests that the 500-bp promoter fragment present in WE assures the same expression profile to the endogenous WAS promoter in granulocyte colonies. In contrast, WE-transduced BFU-E and CFU-M colonies do not achieve similar expression levels between eGFP and endogenous WASp (eGFP-MFI-Inc ratios for BFU-E/ CD34 and CFU-M/CD34 are 0.27 and 0.32 respectively, as compared to 0.76 and 0.83 for endogenous WASp) (Figure 1d ). Therefore, it cannot be excluded that the 500-bp promoter fragment might be lacking some regulatory sequences especially relevant in the erythroid and the monocyte/macrophage differentiation pathway.
Improved expression in erythrocytes, macrophages and megakaryocytes by insertion of a 386-bp fragment of the WAS alternative promoter into WE vector
To improve transgene expression in CD34-derived macrophages and erythroid cells, we inserted part of the WAS alternative promoter, which has been proposed to be especially relevant in myeloid differentiation. 29 We designed an LV (AWE), carrying a 386-bp fragment of the WAS alternative promoter immediately upstream of the 500-bp WAS promoter in the WE vector (Figure 2a) . First, we transduced a panel of haematopoietic cells from lymphoid (Allo-N, Allo-W, Jurkat and Raji) and myeloid (THP-1, HL-60 and K562) lineage and we found that AWE vector achieved an improved expression in myeloid cells, and a fivefold improved expression in the erythroleukaemic K-562 cell line when compared with the WE vector (see Supplementary Material, Supplementary Figure S1 ).
Second, umbilical cord blood (UCB)-CD34 + cells were transduced with SE, WE and AWE vectors and then differentiated into myeloid colonies in vitro. We confirmed that transduced CD34 + cells and their derived colonies contained between 1 and 2 vector copies per cell for the three vector types (data not shown). The incorporation of the alternative WAS promoter into the An additional important feature of WAS disease is the reduced platelet numbers released from megakaryocytes. Therefore, we found it was essential to compare WE and AWE expression profiles in in vitro-generated megakaryocytes derived from transduced CD34 + cells. Both vectors achieved stable expression in immature (CD41a + /CD42b À ) and mature (CD41a + /CD42b + ) megakaryocytes, with AWE vector showing a slightly increased MFI (Figure 3 ). In conclusion, the overall transgene expression profile of the AWE vector in myeloid lineages, derived in vitro from transduced (Figure 4a , upper panels). For WE, as for AWE vectors, the more mature SP4 and SP8 subpopulations expressed eGFP at similar high MFI (Figure  4a ), which were 1.5-to 2-fold higher than the expression obtained by these vectors in the BM CD34 + population (Figures 5b and c) . It is worth noting that for WE as well as for AWE vector, eGFP expression levels in mature CD3 + T cells from the peripheral blood or spleen were maintained or even higher than in BM-CD34 + cells (Figures 5b and c) . In contrast, SE vector expression for thymic sub-populations dropped dramatically as compared to the CD34 + cells in the BM and other lymphoid lineages such as B cells (for example, MFI-Inc SP4 ¼ 115 ± 59 vs MFI-Inc CD34 + ¼ 561 ± 500; and MFIInc spleen CD19 + ¼ 428±262; Figure 5a ). Moreover, CD3 + T cells in the spleen and peripheral blood showed a similar low-level expression (Figure 5a ). Next, we compared AWE and WE expression profiles in B cells and natural killer cells. AWE eGFP expression levels were slightly higher than those obtained by WE in peripheral and splenic B lymphocytes (Figures 4b, 5b  and c) . However, the MFI-Inc of both AWE and WE vectors in BM CD19
+ were similar and did not decrease when compared to the MFI-Inc of early progenitor CD34 + cells or CD13 + cells (Figures 5b and c) . In addition, both WE and AWE vectors behave similarly in BM and splenic CD56 + cells maintaining similar expression profiles as compared to progenitor cells. In summary, both AWE and WE vectors support high-level expression in lymphoid lineages after long-term in vivo human haematopoietic reconstitution.
AWE vector strongly improves expression in in vivo-differentiated myeloid lineages
We observed a different behaviour of WE vs AWE in myeloid lineages as compared to lymphoid lineages. It can be first outlined that SE-driven eGFP levels barely changed between CD34 + cells and the derived myeloid progeny (Figures 5a) . On the contrary, we observed a downregulation in eGFP expression of WE in certain cell types from the myeloid lineage (Figures 4c and 5b, black  bars) . In fact, we observed a striking downregulation in MFI-Inc for the WE vector in CD14 + cells from the spleen (Figures 5b, black bar) (Figure 1) . However, we found that CD14 + cells from BM (BM-CD14 + ) behaved differently to S-CD14 + , as the former downregulated expression only 1.3-fold (Figure 5b) . Finally, in megakaryocytes (CD41 + cells), there is also a 1.8-fold decrease in WE expression levels as compared to BM-CD34 + cells (Figure 5b) . Importantly, the opposite was true after the incorporation of the 386-bp fragment present in the AWE vector, which resulted in an overall increase in eGFP MFI in the myeloid cell types as compared to WE vector (Figures 4c,  5b and c) . First of all, it strikingly improved eGFP MFIInc in CD14 + cells from spleen. Indeed, the MFI-Inc for AWE was 65.04 vs 9.34 obtained with WE, resulting in a sevenfold improved expression level (Figures 5b and c) . In addition, AWE BM-CD14 + cells gave a threefold higher expression (Figures 5b and c Figures 5b and c) .
In summary, the insertion of part of the alternative promoter in AWE vector resulted in an overall improvement of expression in myeloid lineages while sustaining expression in the lymphoid lineage.
Discussion
Ex vivo gene therapy can be a real alternative for WAS patients. Among target cells, HSCs are the most suitable target to transduce as they give rise to the whole haematopoietic system. 34 An ideal gene therapy vector for WAS should transduce HSCs efficiently and maintain transgene levels throughout differentiation, giving the right levels of the transgene in each cell type. The WAS proximal promoter has a key role in haematopoieticspecific expression 29, 30, 35 and has been used before to drive WAS cDNA expression for WAS gene therapy. 24, 25 However, there is no detailed study of the behaviour of these vectors through human haematopoiesis, in part due to the difficulties in obtaining WAS-deficient human HSCs. Therefore, we initially studied the behaviour throughout differentiation of an LV expressing eGFP from the WAS proximal promoter (WE vector).
In vitro, we detected a differential promoter activity according to cell lineage; indeed, in granulocytes, the inserted 500-bp promoter seemed to be regulated as the Abbreviations: eGFP, enhanced green fluorescent protein; FACS, flow cytometry; MOI, multiplicity of infection; rhSCF, recombinant human stem cell factor; rhTPO, recombinant human thrombopoietin. Protocol: 2 Â 10 5 CD34+ cells from cord blood (UCB) were transduced overnight with the indicated vectors (SE, WE, AWE) at MOI ¼ 25 in the presence of rhSCF and rhTPO, rendering around 30% of transduction. Cells were washed and injected intrahepatically to sublethally irradiated 4-day-old Rag 2 À/À , gc À/À Balb-c mice. The animals were killed after 8-10 weeks and bone marrow, spleen and thymus were extracted and analysed through FACS for human engraftment (% total hCD45+ cells) and eGFP-expressing human cells (% transduced hCD45+ cells). Independent experiments were performed with UCB-CD34+ cells from different donors as well as vector preparations (U1-U7 indicate different UCB donors, L1-L9 account for different vector batches).
Improved lentiviral vectors for WAS gene therapy C Frecha et al
935 endogenous WAS promoter. On the contrary, eGFP levels differed from endogenous WASp in monocytes/macrophages and erythroid cells, as we observed a transgene downregulation after differentiation. This could be due to a lack of regulatory sequences especially relevant for a correct expression in these cells. In the genome, endogenous human WAS gene is regulated by the WAS proximal and the WAS alternative promoter. The first one is 1.6-kb long and enriched in putative transcription factor-binding sequences such as Ets, PU.1, c-Rel, Rel-A and Sp-1, related to haematopoietic specificity and differentiation. [35] [36] [37] Recent studies have demonstrated that the full 1.6-kb version and the 500-bp fragment of the WAS proximal promoter achieved equivalent expression in the context of an LV in mature T, B and dendritic cells from WAS patients. 26 The alternative promoter is located 6-kb upstream the proximal promoter and less characterized, though it has been postulated to be especially relevant for myeloid differentiation. 29 In addition, we determined in silico using the TRANSFAC database, the presence of Sp-1, Ets-2, PU.1, AP-2 and c-Myb binding sequences. These sites were reported to play a role in early development stages 30 of myeloid differentiation. 38 Therefore, we included a 386-bp fragment of the alternative promoter immediately upstream the 500-bp WAS proximal promoter resulting in the novel AWE vector.
In vitro differentiation studies revealed that AWE vector achieved a significant increase in eGFP expression after differentiation of the CD34 + cells into monocytic/ macrophagic and erythroid cells, as compared to the WE vector. In addition, AWE also slightly increases eGFP expression in granulocytes and mature megakaryocytes. However, the inclusion of this extra regulatory fragment 
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C Frecha et al did not achieve entirely the same profile of expression as compared to endogenous WASp. To extend the study to the entire haematopoietic lineage, we used the Rag 2 À/À , gc À/À immunodeficient humanized mouse, which is an excellent model for the engraftment and differentiation of hCD34 + cells into all lineages. 32, 33 We first confirmed that both WE and AWE vectors achieved sustained transgene expression in all thymic sub-populations and mature T cells to the same level as detected in hCD34 + cells in the BM of the reconstituted mice. These results agree with functional restoration of human WASp expression in mouse T cells in a WAS À/À mouse model reconstituted with WWtransduced murine progenitor cells. 28 The in vivo performance of WE vector was markedly better in cells from lymphoid lineage than in myeloid cells. It is worth noting that AWE vector retained the high expression levels detected for WE vector in all lymphoid cell types. These results could mean that both promoters are well regulated in these cell types if we take into account that (1) previous mRNA studies carried out by Parolini et al. 10 showed no difference in WAS mRNA expression between CD34 + and peripheral lymphoid cells, and (2) we had previously shown that only 1.5-2 copies of the WW vector that carries the same backbone as WE, but encodes the full WAS cDNA instead of eGFP, were enough to reach normal transgene levels in WAS À/À patient T-cell lines. 24 It is worthnoting that we show that the SFFV promoter in the context of an LV is specifically downregulated in thymocytes and mature T cells. Nevertheless, it still induces higher expression levels than WE and AWE vectors, as shown also by Charrier et al.
26
On the other hand, in accordance with our in vitro data, we found a striking decrease in in vivo transgene expression in WE-transduced CD14 + cells from the spleen and peripheral blood, but not for BM CD14 + population. These differences could be due to the fact that the spleen is highly enriched with CD14 + macrophages, while the BM contains mainly monocytes. 39, 40 Importantly, AWE vector did improve eGFP expression levels by sevenfold in CD14 + cells from the spleen, by threefold in CD14 + cells from the BM and more than 10-fold in CD14 + cells from the peripheral blood. AWE Table 1 . eGFP, enhanced green fluorescent protein; FACS, flow cytometry; MFI, mean fluorescence intensity.
Improved lentiviral vectors for WAS gene therapy C Frecha et al also slightly improved the expression in megakaryocytes in vivo, which is of importance as microthrombocytopaenia is a classic sign of WAS disease. 7, 16 These data showed that, although the inclusion of AWE promoter does not entirely reconstitute the physiological WASp expression pattern, it improves significantly the expression profile in myeloid lineages. This effect on the myeloid lineages could be explained in part by the presence of additional 15 MZF-1 and 14 Sp1, 5 AML and PU.1 binding sites in the alternative promoter, which are certainly involved in myeloid development. 30, 38, [41] [42] [43] This might account for the improved expression of AWE in de novo-developed monocytes, erythroid cells and, to a lesser extent, in megakaryocytes.
Taken all together, this work gives new, valuable information about the performance of the 500-bp WAS proximal promoter fragment upon haematopoietic differentiation. Here we propose the addition of extra regulatory sequences contained in the 386-bp WAS alternative promoter for further vector optimization in the myeloid lineage, as both promoter fragments could be working together leading to a better transgene expression in myeloid cells, and specially in macrophages, without loosing efficiency of expression in the lymphoid lineage.
Materials and methods

Cell lines and culture media
Primary T cells from WAS patients (ALLO-W) and healthy controls (ALLO-N), both generated by allospecific stimulation, were kindly donated by Dr Molina. They were maintained by allospecific stimulation using mitomycin C treatment of Raji B-cell line weekly as described. 12 Haematopoietic cell lines, Jurkat (T-cell line), Raji (B-cell line) and THP-1 (monocytic cell line), were cultured in RPMI-1640, 10% fetal calf serum, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, sodium pyruvate and antibiotics. K562 (erythroleukaemic) and HL-60 (pro-myelocytic) cell lines were cultured in Iscove's medium, IMDM, with antibiotics, with 10% fetal calf serum and 20% fetal calf serum, respectively. UCBderived CD34 + human cells were seeded in StemSpan medium (Stem Cell Technologies, Vancouver, Canada) supplemented with 50 ng ml À1 recombinant human stem cell factor (rhSCF), 10 ng ml À1 recombinant human thrombopoietin (Peprotech EC, London, UK) and penicillin/streptomycin mixture (hereafter complete StemSpan). A commercial semisolid medium with recombinant cytokines (rhSCF, rhGM-CSF, rhIL-3, rhErithropoietin) for the differentiation of myeloid human cells (MethoCult, GF H4434; Stem Cell Technologies) was used for in vitro myeloid differentiation assays.
Plasmids, lentiviral constructs and vector production
The human immunodeficiency virus packaging (pCMVDR8.91) and VSV-G (pMD.G) plasmids were kindly provided by D Trono. The LV plasmid SE (previously named pHRSIN-CSEW 31) contains the SFFV LTR that drives the expression of the eGFP. The WE vector carries a 500-bp fragment of the WAS proximal promoter driving the expression of eGFP and it was already described. 24 For the construction of AWE vector, we performed a standard PCR using genomic DNA . This primer pair amplifies a fragment of 386 bp from the WAS alternative promoter, which was cloned into pGEM-T easy vector (Promega, Madison, WI, USA). To obtain AWE vector, we cloned the 386-bp fragment into the EcoRI site of WE vector. Lentiviral vectors were produced by co-transfection of 293T cells with three plasmids. Briefly, (1) Vector plasmid (SE, WE or AWE), (2) pCMVDR8.9 and (3) Envelope plasmid pMD.G as described previously. 44 
Isolation and transduction of human haematopoietic stem cells
Human umbilical cord blood was collected from healthy deliveries at Virgen de las Nieves Hospital (Granada, Spain), with consent of the mother. Samples were diluted 1:3 in Iscove's medium and low-density cells were separated over a Ficoll-hypaque gradient. CD34 + cells were isolated by two rounds of magnetic cell sorting, using microbead-coated anti-CD34 antibodies (Miltenyi Biotech, Berqisch Gladbach, Germany), following the manufacturer's instructions. Cells were stained using a phycoerythrin-conjugated anti-CD34 antibody (Miltenyi Biotech). The purity of CD34 + cells was higher than 95% in all the experiments. Previous to lentiviral transduction, 5 Â 10 4 CD34 + cells were seeded in 48-well plates and incubated overnight in complete StemSpam. Viral supernatants were added at an MOI from 10 to 30 for 8 h, then washed off with StemSpan.
In vitro myeloid differentiation assay
A total of 1-2 Â 10 3 CD34 + cells were seeded onto 35 mm petri dishes in 1.5 ml MethoCult containing rhSCF, rhGM-CSF, rhIL-3 and rhErithropoietin. The plates were incubated at 37 1C, 5% CO 2 , for 14-16 days, then colonies were counted and analysed under a fluorescence microscope (Cell R IX 81; Olympus, Center Valley, PA, USA) using the same settings for non-transduced, SE-and WEtransduced colonies. Images were captured with a digital camera (Orca CCD; Hamamatsu, Japan).
To quantify eGFP expression achieved by the different vectors and to compare it with endogenous WASp content, the different colonies derived form SE-, WE-or AWE-transduced CD34 + cells were picked. On average, 100 colonies from the same type (CFU-M, CFU-G and BFU-E) were pooled to obtain enough cells to analyse (1) . We used mouse anti-WASp (clone D1; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit anti-Erk antibodies (Anti-MAP Kinase 1/2; Upstate Biotechnology, Dundee, UK) followed by incubation with horseradish peroxidase-labelled antimouse and anti-rabbit antibodies (1:10 000 dilution; Caltag/Invitrogen, Carlsbad, CA, USA).
DNA preparation and quantitative PCR
Genomic DNA was extracted using a genomic DNA extraction kit (Promega). The real-time PCR were performed in the ABI Prism 7000 PCR Detection System (Applied Biosystems, Foster City, CA, USA) using hotstart DNA polymerase (Eppendorf AG, Hamburg, Germany). Vector copy number determination was done by amplification and detection of the eGFP-inserted gene. Primers: Conditioning and reconstitution of Rag 2 À/À , gc À/À Balc mice
Freshly isolated UCB-CD34
+ were transduced overnight with WE, SE or AWE vectors, at MOI 25 as described above. At day 3 post-transduction, 2 Â 10 5 cells were injected intrahepatically into sublethally irradiated 2-to 4-day-old newborn Rag 2 À/À , gc À/À mice (2 Â 1.5 Gy). The animals were kept for 8-10 weeks under sterile conditions. The mice were killed in agreement with bioethical procedures and BM, spleen, thymus and peripheral blood were extracted. Cells were separated from the tissues using a mesh, and the mononuclear cell fraction was obtained from a Ficoll density gradient (Ficoll-Hypaque; Beckman-Coulter, Fullerton, CA, USA).
Flow cytometry analyses
PE-Cy5-conjugated anti-hCD45 antibody was used for the detection of total human cell engraftment in each haematopoietic tissue. APC-coupled antibodies were used for the detection of hCD3 (total T cells), hCD56 (natural killer), hCD19 (B cells), hCD34 (progenitor cells), hCD13 (more mature progenitors), hCD4 (monocytes/CD4 T cells). PE-coupled antibodies were used for the detection of hCD20 (mature B cells), hCD14 (myeloid cells), hCD41 (megakaryocytes), hCD8 (CD8 T cells). All antibodies were obtained from Pharmingen (San Jose, CA, USA).
